MediWound (NASDAQ:MDWD – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday. Separately, HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of MediWound in a report on Wednesday, November 22nd. Get […]
StockNews.com downgraded shares of MediWound (NASDAQ:MDWD – Free Report) from a hold rating to a sell rating in a research report sent to investors on Thursday. Separately, HC Wainwright reaffirmed a buy rating and issued a $26.00 target price on shares of MediWound in a report on Wednesday, November 22nd. Check Out Our Latest Stock […]
HC Wainwright restated their buy rating on shares of MediWound (NASDAQ:MDWD – Free Report) in a research report report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $26.00 price objective on the biopharmaceutical company’s stock. Several other brokerages also recently issued reports on MDWD. StockNews.com downgraded MediWound from a hold rating to […]
MediWound (NASDAQ:MDWD – Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.21, MarketWatch Earnings reports. MediWound had a negative return on equity of 71.45% and a negative net margin of 55.53%. During the same quarter […]
NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand EscharEx® Phase III study.